scholarly journals Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial

2012 ◽  
Vol 64 (7) ◽  
pp. 2387-2397 ◽  
Author(s):  
Lesley M. Arnold ◽  
Ian Hirsch ◽  
Paul Sanders ◽  
Amanda Ellis ◽  
Bernadette Hughes
Keyword(s):  
Clinical Trial ◽  
Multicenter Clinical Trial ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Double Blind Placebo

scholarly journals A Multisite, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin for Treating Cocaine Dependence

2013 ◽  
Vol 70 (6) ◽  
pp. 630 ◽  
Author(s):  
Eugene C. Somoza ◽  
Douglas Winship ◽  
Charles W. Gorodetzky ◽  
Daniel Lewis ◽  
Domenic A. Ciraulo ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Cocaine Dependence ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Double Blind Placebo

scholarly journals Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
A. A. Harandi ◽  
R. Abolfazli ◽  
A. Hatemian ◽  
K. Ghragozlee ◽  
M. Ghaffar-Pour ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Ischemic Stroke ◽  
Treatment Group ◽  
Repeated Measures ◽  
Motor Recovery ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Stroke Treatment ◽  
Double Blind Placebo

Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke.Methods. This study was a double-blind, placebo-controlled clinical trial on 150 patients with a recent (less than 1 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard stroke treatment for 3 months.Results. Sex, age, elapsed time from stroke onset, and risk factors in the treatment group were not significantly different from placebo group at baseline (P>.05). Repeated measures analysis showed that Fugl-Meyer assessment was significantly higher in the treatment group during 12 weeks after stroke (P<.001). Good tolerability to treatment was shown, and adverse events were mild and transient.Conclusion. MLC601 showed better motor recovery than placebo and was safe on top of standard ischemic stroke medications especially in the severe and moderate cases.

Sign in / Sign up

Export Citation Format

Share Document